Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2017) 130 (Supplement 1): 428.

https://doi.org/10.1182/blood.V130.Suppl_1.428.428

Published: 2017

Journal Articles

Idelalisib-Rituximab Results in Considerable Toxicity but Induces Durable Clinical Remissions in Patients with TP53 Disrupted B Cell Prolymphocytic Leukemia

Toby A. Eyre, MBBChir, MRCP, Christopher P. Fox, MBChB, PhD, Ali Boden, MRCP, Adrian Bloor, Moez Dungawalla, Paneesha Shankara, Richard Went, Anna Schuh, MD PhD

Blood (2017) 130 (Supplement 1): 4068.

https://doi.org/10.1182/blood.V130.Suppl_1.4068.4068

Published: 2017

Journal Articles

Successful Salvage of Refractory Burkitts Lymphoma Using Maximum Intensity of the DA EPOCH-R Regimen—a Case Report

Andrew K. McMillan, FRCP, Sarah Hartley, MBBS, MRCP, Catherine Loughran, Mark Bishton, Eleanor James, Catherine Griffiths, Faith Richardson, Christopher P Fox, MBChB PhD

Blood (2017) 130 (Supplement 1): 5229.

https://doi.org/10.1182/blood.V130.Suppl_1.5229.5229

Published: 2017

Journal Articles

Attainment of Complete Remission Is Significantly Associated with Longer Survival Outcomes in Relapsed/Refractory (R/R) CLL: A Meta-Analysis

Varun Ektare, MPH, Christopher P. Fox, MBChB, PhD, Rod S Taylor, MSc, PhD, Inocencio J Timothy, PharmD, PhD, German E Pena, MD, Johnathan C Maher, PhD, Sonya J. Snedecor, PhD

Blood (2016) 128 (22): 2045.

https://doi.org/10.1182/blood.V128.22.2045.2045

Published: 2016

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL

Susan O'Brien, MD, Samantha Jaglowski, MD MPH, John C. Byrd, MD, Rajat Bannerji, MD PhD, Kristie Blum, MD, Christopher P. Fox, MBChB, PhD, Richard R. Furman, MD, Peter Hillmen, Thomas J. Kipps, MD, Marco Montillo, MD, Jeff Sharman, MD, Sam Suzuki, MS, MBA, Danelle James, MD MAS, Alvina D. Chu, MD, Steven Coutre, MD

Blood (2015) 126 (23): 4153.

https://doi.org/10.1182/blood.V126.23.4153.4153

Published: 2015

NARROW

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Idelalisib-Rituximab Results in Considerable Toxicity but Induces Durable Clinical Remissions in Patients with TP53 Disrupted B Cell Prolymphocytic Leukemia

Successful Salvage of Refractory Burkitts Lymphoma Using Maximum Intensity of the DA EPOCH-R Regimen—a Case Report

Attainment of Complete Remission Is Significantly Associated with Longer Survival Outcomes in Relapsed/Refractory (R/R) CLL: A Meta-Analysis

Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL

Email alerts

ASH Publications

American Society of Hematology

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Idelalisib-Rituximab Results in Considerable Toxicity but Induces Durable Clinical Remissions in Patients with TP53 Disrupted B Cell Prolymphocytic Leukemia

Successful Salvage of Refractory Burkitts Lymphoma Using Maximum Intensity of the DA EPOCH-R Regimen—a Case Report

Attainment of Complete Remission Is Significantly Associated with Longer Survival Outcomes in Relapsed/Refractory (R/R) CLL: A Meta-Analysis

Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only